-
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner October 10th, 2019, Bangkok, Thailand — Today, Red Herring announced its Top 100 Asia award winners in recognition of the leading private companies from the region, celebrating these startups’ innovations and technologies across their respective industries. Red Herring Top 100 Asia enlists outstanding entrepreneurs and promising companies. It selects the award winners from approximately 1000 privately financed companies each year in the Asia. Since 1996, ...Oct. 15. 2019 -
EOFLOW Chosen as Company of the Year
EOFLOW made it to the 'Top 10 Diabetes Care Solutions Providers - 2019' list and was chosen as the Company of the Year by Medtech Outlook magazine (see the attachment for a reprint). One can read more about it at: https://diabetes-care.medicaltechoutlook.com/vendors/top-diabetes-care-companies.htmlOct. 07. 2019 -
Menarini Diagnostics & EOFlow sign a long term business agreement
EOFlow Co., Ltd. and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of Innovative Insulin Patch Pump Seoul, South Korea and Florence, Italy 17 September 2019 – EOFlow Co., Ltd., developer of novel wearable drug delivery solutions, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the Insulin Patch Pump product developed by EOFlow Co., Ltd. “We are very pleased and excited to work with A. Menarini Diagno...Sep. 17. 2019 -
EOFLOW Receives Breakthrough Device Designation from FDA
EOFlow Receives FDA Breakthrough Device Designation on its Integrated Wearable Automated Insulin Delivery System SAN JOSE, USA and SEOUL, South Korea, March 14, 2019 EOFLOW CO., Ltd., an emerging medical device company with offices in Seoul, South Korea and San Jose, California, announced today that its closed loop Automated Insulin Delivery /Artificial Pancreas Device (AID/AP), the EOPancreas System, has received Breakthrough Device Designation by the U.S. Food and Drug Administration. The EOPancreas System is designed to pr...Mar. 14. 2019 -
EOFLOW exhibits at EASD 2016, Munich
EOFLOW exhibits its commercial EOPatch wearable disposable insulin delivery product at the 52st EASD (European Association for the Study of Diabetes) Annual Meeting held in Munich, Germany, 9/12-16. EOFLOW's booth is Q.02.Aug. 29. 2016 -
EOFLOW exhibits at ADA 2016, New Orleans
EOFLOW exhibits the latest working sample of EOPatch wearable disposable insulin delivery product at a business partner’s booth at the 76th Scientific Sessions of ADA (American Diabetes Association) held in New Orleans, LA, 06/10-14.Jul. 12. 2016 -
EOFLOW is covered in another newspaper article
Aju News, a major economics newspaper in Korea, runs an article on EOFLOW and its EOPatch wearable disposable insulin pump. To read the Korean article, click the link below: http://www.ajunews.com/view/20160615013058993Jul. 12. 2016 -
EOFLOW exhibits at 2016 KIMES
EOFLOW has exhibited its EOPatch wearable disposable insulin pump products at the 2016 Korea International Medical & Hospital Equipment Show (KIMES). Many potential business partners and end users visited our booth, with a significant number of Type-1 diabetic patients adding their names to the growing list of clinical trial volunteers.Mar. 21. 2016 -
EOFLOW moves in to a new campus
Eoflow has moved to a new location in Healthcare Innovation Park (HIP) run by Seoul National University Bundang Hospital (SNUH), located in Bundang, Korea. The new building is located in a 45,000m^2 campus situated at the foot of a green hill and boasts more than 78,000m^2 of office space. HIP promises to be a major healthcare innovation hub in Korea that nurtures synergistic business opportunities by facilitating cooperation among medical facilities, universities and healthcare companies large and small. HIP is not just a phy...Mar. 21. 2016 -
EOFLOW members appear in a major newspaper
EOFLOW and seven others were asked to pose for an article of a major newspaper covering the successes of TIPS, an important angel investment and incubation program initiated by the Korean government. Read the article in Korean at the newspaper website: http://news.joins.com/article/19699337Mar. 10. 2016 -
EOFLOW announces the funding closure
EOFLOW announces that it just closed its latest round of funding. ‘With this round, we have secured enough funds to complete the product development work and regulatory approvals of our EOPatch insulin delivery product,’ says the company.Oct. 06. 2015 -
EOFLOW exhibits at EASD 2015, Stockholm
EOFLOW exhibits a functional EOPatch wearable disposable insulin delivery product sample at the 51st EASD (European Association for the Study of Diabetes) Annual Meeting held in Stockholm, Sweden, 9/14-18. This is the first time ever that a functional EOPatch is displayed at a public event. Unlike in the previous events, EOFLOW has its own booth.Sep. 01. 2015 -
EOFLOW exhibits at ADA 2015, Boston
EOFLOW exhibits the latest prototype of EOPatch wearable disposable insulin delivery product sample at a business partner’s booth at the 75th Scientific Sessions of ADA (American Diabetes Association) held in Boston, MA, 06/05-09. This is the first time that EOPatch is introduced in a public event in the US.Jun. 01. 2015 -
EOFLOW is covered in an article
Venture Square, an online webzine that covers Korean start-up companies, runs an article on EOFLOW. To read the Korean article, click the link below: http://www.venturesquare.net/583394Apr. 30. 2015
Healthcare Innovation Park #H2102 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
